NFKB1 and lung adenocarcinoma: Interestingly, one comparison investigated breast cancer cells with both estradiol and TNFa treatment for 40 min (57) (6 genes, FDR-adjusted P-value = 5.34 × 10−4), and another which investigated ‘11–18’ lung adenocarcinoma cell line after pharmacological activation and inactivation of NF-κB (64) (5 genes, FDR-adjusted P-value = 2.66 × 10−3) (Supplementary Figure S8).